This trial will test the effects of ozanimod on cognitive processing speed in 250 subjects with relapsing multiple sclerosis over the course of 36 months. The primary efficacy endpoint is the proportion of subjects with a clinically meaningful increase in raw score of ≥ 4 points or 10% from baseline (improved). There is no planned protocol extension following the end of the study.
1 Primary · 20 Secondary · Reporting Duration: Up to approximately 3 years
Experimental Treatment
250 Total Participants · 1 Treatment Group
Primary Treatment: RPC-1063 · No Placebo Group · Phase 3
Age 18 - 65 · All Participants · 7 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:New York | 66.7% |
North Carolina | 33.3% |
18 - 65 | 100.0% |
Weill Cornell Medical College | 100.0% |
Did not meet criteria | 50.0% |
Met criteria | 50.0% |